Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile

Published

News published by Avalyn Pharma concerning AP01 (inhaled pirfenidone), administered via an optimized eFlow® Technology nebulizer.
 

Read the press release

Back to overview